These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 33821267)

  • 1. Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variants.
    Cho H; Gonzales-Wartz KK; Huang D; Yuan M; Peterson M; Liang J; Beutler N; Torres JL; Cong Y; Postnikova E; Bangaru S; Talana CA; Shi W; Yang ES; Zhang Y; Leung K; Wang L; Peng L; Skinner J; Li S; Wu NC; Liu H; Dacon C; Moyer T; Cohen M; Zhao M; Lee FE; Weinberg RS; Douagi I; Gross R; Schmaljohn C; Pegu A; Mascola JR; Holbrook M; Nemazee D; Rogers TF; Ward AB; Wilson IA; Crompton PD; Tan J
    bioRxiv; 2021 Apr; ():. PubMed ID: 33821267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern.
    Cho H; Gonzales-Wartz KK; Huang D; Yuan M; Peterson M; Liang J; Beutler N; Torres JL; Cong Y; Postnikova E; Bangaru S; Talana CA; Shi W; Yang ES; Zhang Y; Leung K; Wang L; Peng L; Skinner J; Li S; Wu NC; Liu H; Dacon C; Moyer T; Cohen M; Zhao M; Lee FE; Weinberg RS; Douagi I; Gross R; Schmaljohn C; Pegu A; Mascola JR; Holbrook M; Nemazee D; Rogers TF; Ward AB; Wilson IA; Crompton PD; Tan J
    Sci Transl Med; 2021 Oct; 13(616):eabj5413. PubMed ID: 34519517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern.
    Yuan M; Chen X; Zhu Y; Dong X; Liu Y; Qian Z; Ye L; Liu P
    J Virol; 2022 Aug; 96(16):e0077522. PubMed ID: 35916510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike.
    Changrob S; Fu Y; Guthmiller JJ; Halfmann PJ; Li L; Stamper CT; Dugan HL; Accola M; Rehrauer W; Zheng NY; Huang M; Wang J; Erickson SA; Utset HA; Graves HM; Amanat F; Sather DN; Krammer F; Kawaoka Y; Wilson PC
    mBio; 2021 Dec; 12(6):e0297521. PubMed ID: 34781736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel bispecific human antibody platform specifically targeting a fully open spike conformation potently neutralizes multiple SARS-CoV-2 variants.
    Kim JW; Heo K; Kim HJ; Yoo Y; Cho HS; Jang HJ; Lee HY; Ko IY; Woo JR; Cho YB; Lee JH; Yang HR; Shin HG; Choi HL; Hwang K; Kim S; Kim H; Chun K; Lee S
    Antiviral Res; 2023 Apr; 212():105576. PubMed ID: 36870394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross neutralization of emerging SARS-CoV-2 variants of concern by antibodies targeting distinct epitopes on spike.
    Wilson P; Changrob S; Fu Y; Guthmiller J; Halfmann P; Li L; Stamper C; Dugan H; Accola M; Rehrauer W; Zheng NY; Huang M; Wang J; Erickson S; Utset H; Graves H; Amanat F; Sather DN; Krammer F; Kawaoka Y
    Res Sq; 2021 Jul; ():. PubMed ID: 34312615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants.
    Haslwanter D; Dieterle ME; Wec AZ; O'Brien CM; Sakharkar M; Florez C; Tong K; Rappazzo CG; Lasso G; Vergnolle O; Wirchnianski AS; Bortz RH; Laudermilch E; Fels JM; Mengotto A; Malonis RJ; Georgiev GI; Quiroz JA; Wrapp D; Wang N; Dye KE; Barnhill J; Dye JM; McLellan JS; Daily JP; Lai JR; Herbert AS; Walker LM; Chandran K; Jangra RK
    mBio; 2021 Oct; 12(5):e0247321. PubMed ID: 34607456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodies.
    Wang Y; Zhang X; Ma Y; Wang Y; Zhan W; Zheng Q; Zhang M; Ji P; Liu M; Liu Q; Sun T; Zhu T; Wen Y; Sun L; Zhao J; Wu F; Chen Z; Huang J
    Cell Discov; 2022 Oct; 8(1):104. PubMed ID: 36207299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody cocktail effective against variants of SARS-CoV-2.
    Liang KH; Chiang PY; Ko SH; Chou YC; Lu RM; Lin HT; Chen WY; Lin YL; Tao MH; Jan JT; Wu HC
    J Biomed Sci; 2021 Nov; 28(1):80. PubMed ID: 34814920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Biological Functions and Clinical Significance of SARS-CoV-2 Variants of Corcern.
    Akkız H
    Front Med (Lausanne); 2022; 9():849217. PubMed ID: 35669924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoclonal antibodies targeting two immunodominant epitopes on the Spike protein neutralize emerging SARS-CoV-2 variants of concern.
    Kovacech B; Fialova L; Filipcik P; Skrabana R; Zilkova M; Paulenka-Ivanovova N; Kovac A; Palova D; Rolkova GP; Tomkova K; Csokova NT; Markova K; Skrabanova M; Sinska K; Basheer N; Majerova P; Hanes J; Parrak V; Prcina M; Cehlar O; Cente M; Piestansky J; Fresser M; Novak M; Slavikova M; Borsova K; Cabanova V; Brejova B; Vinař T; Nosek J; Klempa B; Eyer L; Hönig V; Palus M; Ruzek D; Vyhlidalova T; Strakova P; Mrazkova B; Zudova D; Koubkova G; Novosadova V; Prochazka J; Sedlacek R; Zilka N; Kontsekova E
    EBioMedicine; 2022 Feb; 76():103818. PubMed ID: 35078012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An RBD bispecific antibody effectively neutralizes a SARS-CoV-2 Omicron variant.
    Yuan M; Zhu Y; Liu G; Wang Y; Wang G; Zhang G; Ye L; Qian Z; Liu P
    One Health Adv; 2023; 1(1):12. PubMed ID: 37521533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies that maintain potency against B.1.617.
    Peng L; Hu Y; Mankowski MC; Ren P; Chen RE; Wei J; Zhao M; Li T; Tripler T; Ye L; Chow RD; Fang Z; Wu C; Dong MB; Cook M; Wang G; Clark P; Nelson B; Klein D; Sutton R; Diamond MS; Wilen CB; Xiong Y; Chen S
    Nat Commun; 2022 Mar; 13(1):1638. PubMed ID: 35347138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies that maintain potency against B.1.617.
    Peng L; Hu Y; Mankowski MC; Ren P; Chen RE; Wei J; Zhao M; Li T; Tripler T; Ye L; Chow RD; Fang Z; Wu C; Dong MB; Cook M; Wang G; Clark P; Nelson B; Klein D; Sutton R; Diamond MS; Wilen CB; Xiong Y; Chen S
    bioRxiv; 2021 Dec; ():. PubMed ID: 34981065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2.
    Huang KA; Zhou D; Tan TK; Chen C; Duyvesteyn HME; Zhao Y; Ginn HM; Qin L; Rijal P; Schimanski L; Donat R; Harding A; Gilbert-Jaramillo J; James W; Tree JA; Buttigieg K; Carroll M; Charlton S; Lien CE; Lin MY; Chen CP; Cheng SH; Chen X; Lin TY; Fry EE; Ren J; Ma C; Townsend AR; Stuart DI
    Theranostics; 2022; 12(1):1-17. PubMed ID: 34987630
    [No Abstract]   [Full Text] [Related]  

  • 17. A novel bispecific antibody dual-targeting approach for enhanced neutralization against fast-evolving SARS-CoV-2 variants.
    Kim JW; Kim HJ; Heo K; Lee Y; Jang HJ; Lee HY; Park JW; Cho YB; Lee JH; Shin HG; Yang HR; Choi HL; Shim HB; Lee S
    Front Immunol; 2023; 14():1271508. PubMed ID: 37822941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RBD-mRNA vaccine induces broadly neutralizing antibodies against Omicron and multiple other variants and protects mice from SARS-CoV-2 challenge.
    Shi J; Zheng J; Zhang X; Tai W; Odle AE; Perlman S; Du L
    Transl Res; 2022 Oct; 248():11-21. PubMed ID: 35489692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bispecific antibody neutralizes circulating SARS-CoV-2 variants, prevents escape and protects mice from disease.
    De Gasparo R; Pedotti M; Simonelli L; Nickl P; Muecksch F; Cassaniti I; Percivalle E; Lorenzi JCC; Mazzola F; Magrì D; Michalcikova T; Haviernik J; Honig V; Mrazkova B; Polakova N; Fortova A; Tureckova J; Iatsiuk V; Girolamo SD; Palus M; Zudova D; Bednar P; Bukova I; Bianchini F; Mehn D; Nencka R; Strakova P; Pavlis O; Rozman J; Gioria S; Camilla Sammartino J; Giardina F; Gaiarsa S; Hammarström QP; Barnes CO; Bjorkman PJ; Calzolai L; Piralla A; Baldanti F; Nussenzweig MC; Bieniasz PD; Hatziioannou T; Prochazka J; Sedlacek R; Robbiani DF; Ruzek D; Varani L
    bioRxiv; 2021 Mar; ():. PubMed ID: 33501434
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.